Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3137-3143

  Blumenthal, Kimberly G ^a,b   Youngster, Ilan ^a,b,c   Shenoy, Erica S ^a,b   Banerji, Aleena ^a,b   Nelson, Sandra B ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; NAFCILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR; METICILLIN;

ADULT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; GRAM POSITIVE INFECTION; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NEPHRITIS; NEUTROPENIA; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL; SERUM SICKNESS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; URTICARIA; AGED; CHEMISTRY; COHORT ANALYSIS; CROSS REACTION; IMMUNOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CEFAZOLIN; COHORT STUDIES; CROSS REACTIONS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; METHICILLIN; MIDDLE AGED; NAFCILLIN; OUTPATIENTS; RETROSPECTIVE STUDIES;

EID: 84901265708     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02504-13     Document Type: Article

References (67)

1. Solensky R, Khan D. 2010. Drug allergy: an updated practice parameter. Ann. Allergy Asthma Immunol. 105:259-273. http://dx.doi.org/10.1016/j.anai.2010. 08.002.
2. Gell PGH, Coombs R (ed) 1963. The classification of allergic reactions underlying disease, p 317-37. In Clinical aspects of immunology, 1st ed. Blackwell, Oxford, England.
3. Pichler WJ. 2013. Drug allergy: classification and clinical features. In Basow DS (ed), UpToDate. Wolters Kluwer Health, Philadelphia, PA.
4. Weiss ME, Adkinson NF. 1988. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin. Allergy 18:515-540. http://dx.doi.org/10.1111/j.1365-2222.1988.tb02904.x.
5. Maraqa NF, Gomez MM, Rathore MH, Alvarez AM. 2002. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin. Infect. Dis. 34:50-54. http://dx.doi.org/10.1086/338047.
6. Orbak Z, Sepetcigil O, Karakelleoglu C, Gulses S. 2010. Penicillin V-induced drug rash with eosinophilia and systemic symptoms. West Indian Med. J. 59:722-725.
7. Harr T, French LE. 2010. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet. J. Rare Dis. 5:39. http://dx.doi.org/10.1186/1750-1172-5-39.
8. Ferrandiz-Pulido C, Garcia-Patos V. 2013. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Arch. Dis. Child. 98:998-1003. http://dx.doi.org/10.1136/archdischild-2013-303718.
9. Whitman CB, Wike MJ. 2012. Possible case of nafcillin-induced acute interstitial nephritis. Am. J. Health Syst. Pharm. 69:1049-1053. http://dx.doi.org/10.2146/ajhp110357.
10. Presti ME, Janney CG, Neuschwander-Tetri BA. 1996. Nafcillinassociated hepatotoxicity. Report of a case and review of the literature. Dig. Dis. Sci. 41:180-184.
11. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE,Rybak M, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52: 285-292. http://dx.doi.org/10.1093/cid/ cir034.
12. Federman DD, Nabel EG (ed). 2014. Infectious diseases: the clinician's guide to diagnosis, treatment, and prevention. Decker Publishing Inc., Hamilton, Ontario, Canada.
13. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME, Walker S, Wertheim HF, Wilson P, Llewelyn MJ. 2011. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect. Dis. 11:208-222. http://dx.doi.org/10.1016/S1473-3099(10)70285-1.
14. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672. http://dx.doi.org/10.1128/AAC.48.12. 4665-4672.2004.
15. Stryjewski ME, Szcech LA, Benjamin DK, Inrig JK, Jkanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller B, Corey R, Fowler VG. 2007. Use of vancomycin of first generation cephalosporins for the treatment of hemodialysis dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 44:190-196. http://dx.doi.org/10.1086/510386.
16. Schweizer ML, Furuno J, Harris AD, Johnson K, Shardell MD, McGregor JC, Thom KA, Cosgrove SE, Sakoulas G, Perencevich EN. 2011. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect. Dis. 11:279. http://dx.doi.org/10.1186/1471-2334-11-279.
17. González C, Rubio M, Romero-Vivas J, González M, Picazo JJ. 1999. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin. Infect. Dis. 29:1171-1177. http://dx.doi.org/10.1086/313440.
18. Chan KE, Warren HS, Thadhani RI, Steele D, Hymes JL, Maddux FW, Hakim RM. 2012. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J. Am. Soc. Nephrol. 23:1551-1559. http://dx.doi.org/10.1681/ASN.2012010050.
19. Chang FY, Peacock JEJ, Musher DM, Triplett P, MacDonald BB, Mylotte JM, O'Donnell A, Wagener MM, Yu VL. 2003. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 82:333-339. http://dx.doi.org/10.1097/01.md.0000091184.93122.09.
20. Hoppes T, Prikis M, Segal A. 2007. Four cases of nafcillin-Associated acute interstitial nephritis in one institution. Nat. Clin. Pract. Nephrol. 3:456-461. http://dx.doi.org/10.1038/ncpneph0561.
21. Alam MB, Kadoura A, Sathaiah M. 2012. A fatal case of nafcillin-induced hepatotoxicity: a case report and the literature review. Case Rep. Med. 2012:953714. http://dx.doi.org/10.1155/2012/953714.
22. Baker RJ, Pusey CD. 2004. The changing profile of acute tubulointerstitial nephritis. Nephrol. Dial. Transplant. 19:8-11. http://dx.doi.org/10.1093/ndt/gfg464.
23. Pichichero ME. 2005. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-Allergic patients. Pediatrics 115:1048-1057. http://dx.doi.org/10. 1542/peds.2004-1276.
24. Pichichero ME. 2006. Cephalosporins can be prescribed safely for penicillin-Allergic patients. J. Fam. Pract. 55:106-112.
25. Pichichero ME. 2007. Use of selected cephalosporins in penicillin-Allergic patients: a paradigm shift. Diagn. Microbiol. Infect. Dis. 57:13S-18S. http://dx.doi.org/10.1016/j.diagmicrobio.2006.12.004.
26. Patriarca G, D'Ambrosio C, Schiavino D, Larocca LM, Nucera E, Milani A. 1999. Clinical usefulness of patch and challenge tests in the diagnosis of cell-mediated allergy to betalactams. Ann. Allergy Asthma Immunol. 83: 256-266.
27. DePestel DD, Benninger MS, Danzinger L, LaPlante KL, May C, Luskin A, Pichichero M, Hadley JA. 2008. Cephalosporin use in treatment of patients with penicillin allergies. J. Am. Pharm. Assoc. 48:530-540. http://dx.doi.org/10. 1331/JAPhA.2008.07006.
28. Baldwin DS, Levine BB, McCluskey RT, Gallo GR. 1968. Renal failure and interstitial nephritis due to penicillin and methicillin. N. Engl. J. Med. 279:1245-1252. http://dx.doi.org/10.1056/NEJM196812052792302.
29. Mazuryk H, Kastenberg D, Rubin R, Muñoz SJ. 1993. Cholestatic hepatitis associated with the use of nafcillin. Am. J. Gastroenterol. 88: 1960-1962.
30. Bronnimann M, Yawalkar N. 2005. Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy? Curr. Opin. Allergy Clin. Immunol. 5:317-321. http://dx.doi.org/10.1097/01.all.0000173787.65777.77.
31. Bircher AJ. 2013. Exanthematous (morbilliform) drug eruption. In Basow DS (ed), UpToDate. Wolters Kluwer Health, Philadelphia, PA.
32. Praga M, Appel GB. 2013. Clinical manifestations and diagnosis of acute interstitial nephritis. In Basow DS (ed), UpToDate. Wolters Kluwer Health, Philadelphia, PA.
33. Weller P. 2013. Approach to the patient with eosinophilia. In Basow DS (ed), UpToDate. Wolters Kluwer Health, Philadelphia, PA.
34. Wener MH. 2013. Serum sickness and serum sickness-like reactions. In Basow DS (ed), UpToDate. Wolters Kluwer Health, Philadelphia, PA.
35. Bouvresse S, Valeyrie-Allanore L, Ortonne N, Konstantinou MP, Kardaun SH, Bagot M, Wolkenstein P, Roujeau JC. 2012. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet. J. Rare Dis. 7:72. http://dx.doi.org/10. 1186/1750-1172-7-72.
36. Bocquet H, Bagot M, Roujeau JC. 1996. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin. Cutan. Med. Surg. 15:250-257. http://dx.doi.org/10. 1016/S1085-5629(96)80038-1.
37. Yang J, Yang X, Li M. 2013. Peripheral blood eosinophil counts predict the prognosis of drug eruptions. J. Investig. Allergol. Clin. Immunol. 23: 248-255.
38. Paladino J, Poretz D. 2010. Outpatient parenteral antimicrobial therapy today. Clin. Infect. Dis. 51(Suppl 2):S198-S208. http://dx.doi.org/10.1086/ 653520.
39. Chapman ALN, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD. 2009. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J. Antimicrob. Chemother. 64:1316-1324. http://dx.doi.org/10.1093/jac/dkp343.
40. Barr DA, Semple L, Seaton RA. 2012. Outpatient parenteral antimicrobial therapy (OPAT) in a teaching hospital-based practice: a retrospective cohort study describing experience and evolution over 10 years. Int. J. Antimicrob. Agents 39:407-413. http://dx.doi.org/10.1016/j.ijantimicag.2012.01.016.
41. Cox AM, Malani PN, Wiseman SW, Kauffman CA. 2007. Home intravenous antimicrobial infusion therapy: a viable option in older adults. J. Am. Geriatr. Soc. 55:645-650. http://dx.doi.org/10.1111/j.1532-5415.2007.01133.x.
42. Madhavan T, Quinn EL, Freimer E, Fisher EJ, Cox F, Burch K, Pohlod D. 1973. Clinical studies of cefazolin and comparison with other cephalosporins. Antimicrob. Agents Chemother. 4:525-531. http://dx.doi.org/10.1128/AAC.4.5.525.
43. Quinn EL, Pohlod D, Madhavan T, Burch K, Fisher E, Cox F. 1973. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J. Infect. Dis. 128(Suppl):S386-S389. http://dx.doi.org/10.1093/infdis/128. Supplement-2.S386.
44. Shuford JA, Piper KE, Hein M, Trampuz A, Steckelberg JM, Patel R. 2006. Lack of association of Staphylococcus aureus type A beta-lactamase with cefazolin combined with antimicrobial spacer placement prosthetic joint infection treatment failure. Diagn. Microbiol. Infect. Dis. 54:189-192. http://dx.doi.org/10.1016/j.diagmicrobio.2005.09.015.
45. Wynn M, Dalovisio JR, Tice AD, Jiang X. 2005. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South. Med. J. 98:590-595. http://dx.doi.org/10.1097/01.SMJ.0000145300.28736.BB.
46. Nannini EC, Stryjewski ME, Singh KV, Bourgogne A, Rude TH, Corey GR, Fowler VG, Jr, Murray BE. 2009. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob. Agents Chemother. 53:3437-3441. http://dx.doi.org/10.1128/AAC.00317-09.
47. Nannini EC, Stryjewski ME, Singh KV, Rude TH, Corey GR, Fowler VG, Jr, Murray BE. 2010. Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 54:2206-2208. http://dx.doi.org/10.1128/AAC.01325- 09.
48. Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, Gainer B, Kunkel MJ, Yancey RW, Williams DN. 2004. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin. Infect. Dis. 38:1651-1672. http://dx.doi.org/10.1086/420939.
49. Faden D, Faden HS. 2009. The high rate of adverse drug events in children receiving prolonged outpatient parenteral antibiotic therapy for osteomyelitis. Pediatr. Infect. Dis. J. 28:539-541. http://dx.doi.org/10.1097/INF. 0b013e318193ef38.
50. Dahlgren AF. 1997. Adverse drug reactions in home care patients receiving nafcillin or oxacillin. Am. J. Health Syst. Pharm. 54:1176-1179.
51. Anonymous. 2004. Drugs for sexually transmitted infections. Treat. Guidel. Med. Lett. 2:67-74.
52. Smego RA, Foglia G. 1998. Actinomyces. Clin. Infect. Dis. 26:1255-1261. http://dx.doi.org/10.1086/516337.
53. Dodge RA, Daly JS, Davaro R, Glew RH. 1997. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multiresistant enterococci. Clin. Infect. Dis. 25:1269-1270. http://dx.doi.org/10.1086/516977.
54. Tally FP, Gorback SL. 1985. Therapy of mixed anaerobic-Aerobic infections. Lessons from intra-Abdominal sepsis. Am. J. Med. 78:145-153.
55. Murphy EC, Frick IM. 2013. Gram-positive anaerobic cocci-commensals and opportunistic pathogens. FEMS Microbiol. Rev. 37:520-553. http://dx.doi.org/10. 1111/1574-6976.12005.
56. Cohen SE, Klausner JD, Engelman J, Philip S. 2013. Syphilis in the modern era: an update for physicians. Infect. Dis. Clin. North Am. 27: 705-722. http://dx.doi.org/10.1016/j.idc.2013.08.005.
57. Norton K, Ingram PR, Heath CH, Manning L. 2014. Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital. J. Antimicrob. Chemother. 69:805-808. http://dx.doi.org/10.1093/jac/dkt402.
58. Rybak M, Lomaestro B, Rotschaefer JC, Moellering RJ, Craig W, Billeter M, Dalovisio JR, Levine DP. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98. http://dx.doi.org/10.2146/ajhp080434.
59. Tacconelli E, Cataldo MA. 2008. Vancomycin-resistant enterococci (VRE): transmission and control. Int. J. Antimicrob. Agents 31:99-106. http://dx.doi.org/10.1016/j.ijantimicag.2007.08.026.
60. Hospital Infection Control Practices Advisory Committee (HICPAC). 1995. Recommendations for preventing the spread of vancomycin resistance. Infect. Control Hosp. Epidemiol. 16:105-113.
61. Tan SK, Tay YK. 2012. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm. Venereol. 92:62-66. http://dx.doi.org/10.2340/00015555- 1169.
62. Blanca M, Torres MJ, Garcia JJ, Romano A, Mayorga C, de Ramon E, Vega JM, Miranda A, Juarez C. 1999. Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics. J. Allergy Clin. Immunol. 103(Pt 1):918-924. http://dx.doi.org/10.1016/S0091-6749(99) 70439-2.
63. Macy E, Ngor E. 2013. Safely diagnosing clinically significant penicillin allergy using only penicilloyl-poly-lysine. J. Allergy Clin. Immunol. Pract. 1:258-263. http://dx.doi.org/10.1016/j.jaip.2013.02.002.
64. Barbaud A. 2009. Skin testing in delayed reactions to drugs. Immunol. Allergy Clin. North Am. 29:517-535. http://dx.doi.org/10.1016/j.iac.2009.04.010.
65. Wolkenstein P, Chosidow O, Fléchet ML, Robbiola O, Paul M, Dumé L, Revuz J, Roujeau JC. 1996. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 35:234-236. http://dx.doi.org/10.1111/j.1600- 0536.1996.tb02364.x.
66. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K, Pichler WJ, Demoly P, ENDA, EAACI. 2004. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 59:1153-1160. http://dx.doi.org/10.1111/j.1398- 9995.2004.00678.x.
67. Romano A, Quaratino D, Di Fonso M, Papa G, Venuti A, Gasbarrini G. 1999. A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. J. Allergy Clin. Immunol. 103:1186-1190. http://dx.doi.org/10.1016/S0091- 6749(99)70197-1.